Related Experiment Videos

Astrocytes convert the parkinsonism inducing neurotoxin, MPTP, to its active metabolite, MPP+

Neuroscience Letters
|April 10, 1987
PubMed

Insights

Astrocytes convert 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into its toxic form, MPP+. Chronic MPTP exposure damages astrocytes, but this neurotoxic effect can be mitigated by monoamine oxidase inhibitors.

Area of Science:

  • Neuroscience
  • Toxicology
  • Cell Biology

Background:

  • 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin implicated in Parkinsonism.
  • Astrocytes play crucial roles in central nervous system homeostasis and neuronal support.

Purpose of the Study:

  • To investigate the role of astrocytes in the metabolism of MPTP.
  • To determine the direct toxic effects of MPTP on astrocytes.

Main Methods:

  • Primary astrocyte cultures were exposed to MPTP.
  • MPP+ concentrations were measured using analytical techniques.
  • Glial density was assessed after MPTP exposure.
  • The effect of pargyline, a monoamine oxidase inhibitor, was evaluated.

Main Results:

  • Cultured astrocytes efficiently converted MPTP to MPP+ within toxic ranges for neurons.
  • MPTP exposure reduced glial density, indicating astrocyte toxicity.
  • Pargyline inhibited MPTP to MPP+ conversion by 85% and blocked MPTP's toxic effects on glial density.
  • Co-culturing with neurons did not enhance MPTP conversion by astrocytes.

Conclusions:

  • Astrocytes are critical in metabolizing MPTP to its toxic MPP+ form.
  • Astrocytes are susceptible to damage from chronic MPTP exposure.
  • Monoamine oxidase inhibitors can protect astrocytes from MPTP-induced toxicity.

Related Concept Videos